RecruitingGlandSalivary Gland Cancers
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Sponsor: M.D. Anderson Cancer Center
You may qualify if…
- ✓ All patients must meet all of the following inclusion criteria to be eligible for participation in this study:
- ✓ 1. Patients ≥18 years with histology-proven R/M salivary gland cancer.
- ✓ 2. Not amenable to curative intent surgery or radiotherapy
- ✓ 3. Measurable disease per RECIST 1.1
- ✓ 4. Performance status ECOG of 0 or 1
- ✓ 5. Patient has provided informed consent.
- ✓ 6. Laboratory measurements, blood counts:
- ✓ 1. Hemoglobin ≥ 9 g/dL. Red blood cell transfusions are permitted to meet the hemoglobin inclusion criteria
You may not qualify if…
- ✕ Patients who meet any of the following exclusion criteria are not eligible to be enrolled in this study:
- ✕ 1. Prior radiation therapy (or other non-systemic therapy) within 2 weeks prior to enrollment
- ✕ 2. Active CNS disease (patients with asymptomatic and stable, treated CNS lesions who have been off corticosteroids, radiation, or other CNS-directed therapy for at least 4 weeks are not considered active)
- ✕ 3. Red blood cell transfusion dependence, defined as requiring more than 2 units of packed RBC transfusions during the 4-week period prior to screening. Red blood cell transfusions are permitted during the screening period and prior to enrollment to meet the hemoglobin inclusion criterion.
- ✕ 4. Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to SG treatment
- ✕ 5. Current participation in another interventional clinical study
- ✕ 6. History of previous malignancy other than malignancy treated with curative intent. Patients with the following diagnoses represents an exception and may enroll if ≥ 1 year with no evidence of active disease before the first dose of the study drug.:
- ✕ 1. Non-melanoma skin cancers with no current evidence of disease
Where it's recruiting
Texas
Houston
Source: ClinicalTrials.gov · NCT05884320 · last updated 2026-07-16